logo
Plus   Neg
Share
Email

Sanofi : EU Okays Libtayo For Advanced Cutaneous Squamous Cell Carcinoma

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF,SNY) said that the European Commission granted conditional marketing authorization for Libtayo or cemiplimab to treat adults with metastatic or locally advanced cutaneous squamous cell carcinoma, who are not candidates for curative surgery or curative radiation.

Cutaneous squamous cell carcinoma is one of the most commonly diagnosed skin cancers worldwide, and and is especially difficult to treat in advanced stages.

Libtayo is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. The recommended dose of Libtayo is 350 mg every 3 weeks administered by intravenous infusion over 30 minutes. Treatment may be continued until disease progression or unacceptable toxicity.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement. Gap Inc. partnered with fashion resale platform thredUP to facilitate the exchange of secondhand cloths. The retailer in a blog post said its customers can bring secondhand clothes in exchange for shopping credit that can be redeemed at Gap, Banana Republic, Athleta, or Janie and Jack. Customers who redeem their credits at Gap brands will receive an additional 15 percent payout bonus. Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference. For fiscal 2020, the company continues to project...
Follow RTT
>